Effect of tandem autologous stem cell transplantation on survival in pediatric patients with high-risk solid tumors in South China

Table 3 Toxicity in patients with solid tumors who underwent tandem autologous stem cell transplantation, n (%)

Parameter	First ASCT		Second ASCT
	Group A (n = 21)	Group B (n = 19)	Group A (n = 21)	Group B (n = 19)
Hematologic toxicity
Fever (BT ≥ 38.0 °C)	17 (81.1)	18 (94.7)	17 (80.1)	16 (84.2)
Septicemia	2 (9.5)	1 (5.3)	0 (0)	0 (0)
Non-hematologic toxicity
Mucositis	1 (4.8)	3 (15.8)	2 (9.5)	5 (26.3)
Vomiting	14 (66.7)	16 (84.2)	12 (57.1)	11 (57.9)
Diarrhea	10 (47.6)	13 (68.4)	10 (47.6)	11 (57.9)
Elevated liver enzymes	4 (19.0)	4 (21.1)	1 (4.7)	4 (21.1)
Renal insufficiency	0 (0)	1 (5.3)	0 (0)	1 (5.3)
Hypokalemia	5 (23.8)	10 (52.6)	2 (9.5)	4 (21.1)
Hypomagnesemia	8 (38.0)	6 (31.6)	7 (33.3)	2 (10.5)
Hepatic VOD	0 (0)	0 (0)	0 (0)	3 (15.8)
Myocarditis	2 (9.5)	1 (5.3)	0 (0)	0 (0)
Treatment-related mortality	0		0

ASCT: Autologous stem cell transplantation; BT: Body temperature; VOD: Veno-occlusive disease.